3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1
3
Phase 3
2
Phase 4
1
Phase 1/2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
21
Lymphoma, Mantle-Cell
10
Lymphoma, Non-Hodgkin
7
Lymphoma
6
Waldenstrom Macroglobulinemia
4
Recurrence
4
Lymphoma, Follicular
4
Lymphoma, B-Cell
4
Bronchiolitis Obliterans Syndrome
3
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, B-Cell
2
Hematologic Diseases
2
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Leukemia, Lymphoid
1
Leukemia
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Hepatitis B, Chronic
1
Graft vs Host Disease
1
Anemia
1
Interventions
ofatumumab
3
venetoclax
2
pirtobrutinib
2
obinutuzumab
2
ibrutinib
2
Chlorambucil
2
acalabrutinib
1
Tablets
1
Observation
1
Cholecalciferol
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Leukemia, B-Cell
×
ibrutinib
×
Clear all
NCT04608318
2026-04-30
CLL17
German CLL Study Group
Phase 3
Active not recruiting
897 enrolled
NCT05254743
2026-04-20
BRUIN-CLL-314
Eli Lilly and Company
Phase 3
Recruiting
662 enrolled